Некоторое содержание этого приложения в настоящий момент недоступно.
Если эта ситуация сохраняется, свяжитесь с нами по адресуОтзывы и контакты
1. (WO2019025391) ANTIBODIES WITH FUNCTIONAL DOMAINS IN THE ELBOW REGION BETWEEN VARIABLE ADN CONSTANT DOMAIN



Отказ от ответственности Графическая версия (PDF), размещенная в PATENTSCOPE, является официальной. Данная html-версия в онлайн служит для удобства пользователей. Несмотря на все приложенные при составлении усилия по обеспечению точного и чёткого отображения данных, содержащихся в печатном документе/на изображениях, нельзя исключать наличия ошибок и/или упущений, связанных с процессами передачи и преобразования данных, а также с ограничениями, изначально присущими процессам (необязательного) машинного перевода. Гиперссылки, предшествующие символу , ведут к внешним ресурсам, находящимся вне компетенции ВОИС. ВОИС отказывается от любой ответственности в этой связи.

INTERNATIONAL SEARCH REPORT (ISR)
Part 1:  1  2  3  4  5  6          Part 2:  A  B  C  D  E 
International application No. Applicant's or agent's file reference
PCT/EP2018/070640 IR01P005WO1
International filing date (day/month/year) (Earliest) Priority Date (day/month/year)
30 July 2018 31 July 2017
Applicant
INSTITUTE FOR RESEARCH IN BIOMEDICINE
FOR FURTHER ACTION: See Form PCT/ISA/220 as well as, where applicable, item 5 below.
This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.
It is also accompanied by a copy of each prior art document cited in this report.
1. Basis of the report
a. With regard to the language, the international search was carried out on the basis of:
the international application in the language in which it was filed.
a translation of the international application into                                          which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
b.
This international search report has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43.6bis(a)).
c.
1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
a. forming part of the international application as filed:
in the form of an Annex C/ST.25 text file.
on paper or in the form of an image file.
b. furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
c. furnished subsequent to the international filing date for the purposes of international search only:
in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2.
In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3.
Additional comments:
2. Certain claims were found unsearchable
3. Unity of invention is lacking
4. Title of the invention
The text is approved as submitted by the applicant.
The text has been established by this Authority to read as follows:
ANTIBODIES WITH FUNCTIONAL DOMAINS IN THE ELBOW REGION BETWEEN VARIABLE ADN CONSTANT DOMAIN

5. Abstract
The text is approved as submitted by the applicant.
The text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. Drawings
a.
The figure of the drawings to be published with the abstract is Figure No.     1b    
as suggested by the applicant.
as selected by this Authority, because the applicant failed to suggest a figure.
as selected by this Authority, because this figure better characterizes the invention.
b.
none of the figures is to be published with the abstract.

A. CLASSIFICATION OF SUBJECT MATTER

     C07K 16/24 (2006.01)i; C07K 16/16 (2006.01)i; C07K 16/00 (2006.01)i; C07K 14/705 (2006.01)i; C07K 16/10 (2006.01)i; C07K 16/12 (2006.01)i
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols):
     C07K
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched:
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used):
EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
(1)
X
WO 2009018386 A1 (MEDIMMUNE LLC [US]; WU HERREN [US]; GAO CHANGSHOU [US]; HAY CARL [US];) 05 February 2009 (2009-02-05)
1-3,7-9,11,16,20,22,26-29,31-34,36-38,40-44,47,48,51-58,61-70
figure 4
(2)
A
WO 2016207402 A1 (INST FOR RES IN BIOMEDICINE [CH]) 29 December 2016 (2016-12-29)
1-70
(3)
A
JOSHUA TAN ET AL, "A LAIR1 insertion generates broadly reactive antibodies against malaria variant antigens", NATURE,Vol. 529, No. 7584, 23 December 2015 (2015-12-23), page 105-109,
XP055296957
1-70
(4)
A
FU-LIEN HSIEH, "The structure of a LAIR1-containing human antibody reveals a novel mechanism of antigen recognition", ELIFE,Vol. 6, 20 May 2017 (2017-05-20), page 1-11,
XP055426101
1-70
(5)
A
Pavel E Yakovlev, "Discovery and characterization of a high potency anti-inflammatory trispecific TNF-alpha/IL-17 Alpha/IL-17F inhibitor", 29 April 2016 (2016-04-29),
Retrieved from the Internet:
URL:https://www.slideshare.net/PavelYakovlev7/discovery-and-characterization-of-a-high-potency-antiinflammatory-trispecific-tnfil17ail17f-inhibitor
XP055426431
[retrieved on  2017-11-17]
1-70
the whole document
*
Special categories of cited documents:
"A"
document defining the general state of the art which is not considered to be of particular relevance
"E"
earlier application or patent but published on or after the international filing date
"L"
document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"
document referring to an oral disclosure, use, exhibition or other means
"P"
document published prior to the international filing date but later than the priority date claimed
"T"
later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"
document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"
document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"
document member of the same patent family

D. INFORMATION ON PATENT FAMILY MEMBERS

Patent document cited in search report Publication date
(day/month/year)
Patent family member(s) Publication date
(day/month/year)
WO 2009018386 A1
05 February 2009
AU 2008282218 A1
CA 2694488 A1
CN 101952312 A
EP 2069401 A1
EP 2626371 A1
JP 2010535032 A
KR 20100058509 A
US 2009155275 A1
US 2010233173 A1
US 2013295098 A1
WO 2009018386 A1
05 February 2009
05 February 2009
19 January 2011
17 June 2009
14 August 2013
18 November 2010
03 June 2010
18 June 2009
16 September 2010
07 November 2013
05 February 2009
WO 2016207402 A1
29 December 2016
EP 3313871 A1
US 2018179274 A1
WO 2016207402 A1
02 May 2018
28 June 2018
29 December 2016
Name and mailing address of the ISA/:
European Patent Office
P.B. 5818, Patentlaan 2, 2280 HV Rijswijk,
Netherlands
Telephone No. (+31-70)340-2040
Facsimile No. (+31-70)340-3016
Date of the actual completion of the international search:
19 October 2018
Date of mailing of the international search report:
31 October 2018
Authorized officer:
Lechner, Oskar
Top    Part 1: 1 2 3 4 5 6         Part 2: A B C D E